Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure

ELENA MYASOEDOVA, CYNTHIA S. CROWSON, PAULO J. NICOLA, HILAL MARADIT-KREMERS, JOHN M. DAVIS III, VÉRONIQUE L. ROGER, TERRY M. THERNEAU and SHERINE E. GABRIEL
The Journal of Rheumatology August 2011, 38 (8) 1601-1606; DOI: https://doi.org/10.3899/jrheum.100979
ELENA MYASOEDOVA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CYNTHIA S. CROWSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAULO J. NICOLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HILAL MARADIT-KREMERS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN M. DAVIS III
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VÉRONIQUE L. ROGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TERRY M. THERNEAU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHERINE E. GABRIEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gabriel.sherine@mayo.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Tables

    • View popup
    Table 1.

    Characteristics of 795 incident RA patients (1980–2007, Olmsted County, Minnesota) at RA incidence and during the followup. The values are given as number (%) if not indicated otherwise.

    VariableAt RA IncidenceAt Any Time During Followup
    Age, yrs, mean ± SD55.3 ± 15.5—
    Female546 (69)—
    Length of followup, yrs, mean ± SD9.7 ± 6.9—
    Smoking status
      Current171 (22)—
      Former254 (33)—
    Alcohol abuse54 (7)63 (8)
    Hypertension490 (65)676 (88)
    Dyslipidemia431 (57)569 (74)
    Obesity (BMI ≥ 30 kg/m2)302 (41)368 (49)
    Family history of premature coronary heart disease172 (22)—
    Personal history of coronary heart disease72 (10)170 (23)
    Diabetes mellitus77 (11)147 (20)
    • BMI: body mass index.

    • View popup
    Table 2.

    RA characteristics and their associations with the risk of heart failure (HF) in 795 incident RA patients. Values are given as number (%) if not indicated otherwise.

    CharacteristicsValueHazard Ratio ** (95% CI), Adjusted for Age, Sex, and Calendar Year of RA Incidence
    RF-positive527 (66)1.6 (1.0, 2.5)
    ESR at RA incidence, mm/h, mean ± SD24.2 ± 19.91.6 (1.2, 2.0)†
    ≥ 3 ESR ≥ 60 mm/h99 (12)2.1 (1.2, 3.5)
    Large-joint swelling624 (78)1.1 (0.7, 1.8)
    Joint erosions/destructive changes424 (53)1.1 (0.8, 1.7)
    Joint surgery
      Arthroplasty134 (17)1.5 (0.9, 2.5)
      Synovectomy86 (11)1.1 (0.6, 2.2)
    Rheumatoid nodules266 (33)1.1 (0.7, 1.7)
    Severe ExRA*87 (11)3.1 (1.9, 5.1)
    History of rheumatic fever22 (3)1.0 (0.4, 2.7)
    • ↵* Malmö criteria32.

    • ↵** Significant (p < 0.05) hazard ratios are shown in bold type.

    • ↵† Per 30 mm/h increase. RA: rheumatoid arthritis; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; ExRA: extraarticular manifestations of RA.

    • View popup
    Table 3.

    Antirheumatic medications and their associations with risk of heart failure (HF) in 795 incident RA patients.

    Antirheumatic MedicationsN (%)Hazard Ratio * (95% CI), Adjusted for Age, Sex, and Calendar Year of RA Incidence
    Used at any time
      Methotrexate465 (58)0.9 (0.6, 1.5)
      Hydroxychloroquine475 (60)0.9 (0.6, 1.4)
      Other DMARD255 (32)0.9 (0.5, 1.6)
      Biologic response modifiers135 (17)0.8 (0.2, 2.6)
      Corticosteroids614 (77)1.2 (0.7, 1.9)
      NSAID732 (91)1.0 (0.5, 1.9)
      Coxibs386 (49)1.5 (0.9, 2.3)
      ASA330 (43)1.0 (0.6, 1.7)
    Current use
      Methotrexate0.5 (0.3, 0.9)
      Hydroxychloroquine1.0 (0.5, 1.8)
      Other DMARD0.5 (0.2, 1.5)
      Biologic response modifiers0.5 (0.1, 3.5)
      Corticosteroids2.0 (1.3, 3.2)
    • ↵* Significant (p < 0.05) hazard ratios are shown in bold type. DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs; ASA: acetylsalicylic acid for arthritis [> 6 tablets per day (> 1950 mg/day) for at least 3 months]

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 8
1 Aug 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure
ELENA MYASOEDOVA, CYNTHIA S. CROWSON, PAULO J. NICOLA, HILAL MARADIT-KREMERS, JOHN M. DAVIS, VÉRONIQUE L. ROGER, TERRY M. THERNEAU, SHERINE E. GABRIEL
The Journal of Rheumatology Aug 2011, 38 (8) 1601-1606; DOI: 10.3899/jrheum.100979

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Influence of Rheumatoid Arthritis Disease Characteristics on Heart Failure
ELENA MYASOEDOVA, CYNTHIA S. CROWSON, PAULO J. NICOLA, HILAL MARADIT-KREMERS, JOHN M. DAVIS, VÉRONIQUE L. ROGER, TERRY M. THERNEAU, SHERINE E. GABRIEL
The Journal of Rheumatology Aug 2011, 38 (8) 1601-1606; DOI: 10.3899/jrheum.100979
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire